Home / Market News / $ABBV
benzinga Corporate Catalyst Impact 75/100 ● positive

Why is AbbVie (ABBV) Stock Trending After Hours?

Oct 8, 2026, 2:52 AM UTC · Primary ticker $ABBV

AbbVie's investigational drug, telisotuzumab adizutecan (Temab-A), received two Breakthrough Therapy Designations from the FDA for metastatic colorectal cancer and non-small cell lung cancer. This accelerates the development and review process, indicating strong clinical evidence and potential for significant market impact in oncology.

AbbVie announced that its drug Temab-A received two Breakthrough Therapy Designations (BTDs) from the FDA. This is a significant positive development as BTDs are granted to drugs that show substantial improvement over existing therapies and expedite the development and review process. This news is a strong catalyst for AbbVie, particularly in the oncology space, as it validates the potential of Temab-A in treating refractory, metastatic colorectal cancer and non-small cell lung cancer. Short-term, this could lead to continued positive sentiment and upward price movement for ABBV, as seen in after-hours trading. Long-term, successful development and approval of Temab-A could significantly boost AbbVie's pipeline and revenue, positioning it strongly in the competitive cancer treatment market. The key opportunity for traders is the potential for accelerated market entry and future sales growth for ABBV.

$ABBV positive FDA Breakthrough Therapy Designations for key drug
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.